Synergy between IBL-202 and venetoclax against primary CLL cells cultured under conditions that mimic the tumor microenvironment suggests this drug combination may be effective against CLL cells within the lymph nodes and bone marrow. Furthermore, the efficacy of the combination against the TP53-KO OSU-CLL cell line suggests the combination may be a highly effective treatment strategy for high-risk CLL.

4 years ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • BCL2L1 (BCL2-like 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD40LG (CD40 ligand)

MCL1 expression

Venclexta (venetoclax) • IBL-202

over4years

Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma. (PubMed, Leuk Lymphoma)

The results support the efficacy of simultaneously targeting inter-related molecules to overcome apoptotic escape in this biologically heterogeneous disease. As venetoclax, pan-PIM-kinase and pan-PI3-kinase inhibitors have, or are currently being studied in clinical trials, it may be rational to consider these drugs in combination for the treatment of DLBCL.

over 4 years ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1)

BCL2 overexpression • MCL1 expression

Venclexta (venetoclax) • IBL-202